Pedro Gabriel Scardini

4/6yr MS at @EmescamES 🇧🇷| Cardiology Researcher🫀 |Aspirating IM resident 🇺🇸 | STEP 1 👍

[derek guy @dieworkwear]

Alex Pretti reads some final words for a veteran he cared for at a VA hospital. Video courtesy of the veteran's son.

[Tony Breu @tony_breu]

1/13
🤔Why does multiple myeloma cause anemia and not pancytopenia?

If the issue is infiltration of the bone marrow with plasma cells, wouldn't all cell lines be low?

Let's have a look.

[Pasquale Paolisso @P_Paolisso]

👥Retrospective cohort study of Kidney transplant recipients (KTRs) with T2DM with 1:1 Propensity Score Matching (PSM) -> 💊GLP-1 RAs vs no-GLP-1 RAs.

📊Primary outcome: all-cause mortality
Secondary outcomes: MACEs and major adverse kidney events (MAKEs).

💥In KTRs with diabetes, GLP-1 RAs were linked to 39% lower mortality and reduced risks of major CV & kidney events. Yet, their use remains low!
A major opportunity to improve outcomes!

Please read more on #CardiovascularDiabetology👇
https://t.co/KKIXc3YLZU
@BioMedCentral #KidneyTransplant #GLP1RA #CardioRenal

[Eric Shih Katsuyama @erickatsuyama97]

I am honored by the recognition in this incredible work. Many thanks to the @metaacademy_ofc

[Alonzo Armani Prata @Alonzo_Prata]

Honored to be a co-author in this impactful research! Excited to contribute to advancing knowledge in the field. #CardioTwitter #Cardiology #MedX

[Christian Ken Fukunaga @christiankfuku]

Fortunate to contribute to this #MetaAnalysis to @BioMedCentral
Grateful for this huge achievement in cardiology 🫀

[Pasquale Paolisso @P_Paolisso]

👥Systematic meta-analysis of 10 RCTs (>22,000 pts - 51.2% w/T2DM) to determine the impact of SGLT2i in pts w/ recent or previous MI.
🗓️Mean age 62 yrs; median FU was 21 months.

Main findings:
💥HF hospitalization rates were ⬇️in pts on SGLT2i compared with placebo (RR 0.77; 95% CI 0.69, 0.85; p<0.001).

💥These benefits of SGLT2i were consistent regardless of the timing of the last MI.

💥No statistically significant difference in all-cause mortality was observed between the groups (RR 0.88; 95% CI 0.78, 1.00; p=0.058).

Read more on #CardiovascularDiabetology @BioMedCentral 👇
https://t.co/dNKZ0xogjw

[HeartRhythm @hrs_journal]

Cardioneuroablation in Patients with Vasovagal Syncope: An updated systematic review and meta-analysis

@Alonzo_Prata @erickatsuyama97 @christiankfuku, @pedroscardini @VanioAntunes @AnaCCoan

https://t.co/SjX2uZLHkq

[Alonzo Armani Prata @Alonzo_Prata]

After a long period of hard work, got my Step 2 CK score—beyond thrilled! Now closer to my dream! 🇺🇸 🩺
#MedX #MedTwitter #USMLE #Step2 #Step2CK

[Pedro Gabriel Scardini @pedroscardini]

Step 1 done✅! Grateful for all the support from my colleagues. On to the next phase. #MedTwitter #step1

[Heart2Heart Research Group @h2h_research]

Congratulations to our team🫀with the leadership of @pedroscardini

[Pedro Gabriel Scardini @pedroscardini]

🚨 Exciting news! Our meta-analysis on SGLT2i in MI patients has been accepted for publication in Cardiovascular Diabetology!

🔎 Key findings:
✅ SGLT2i reduced MACE events &amp; heart failure hospitalizations
✅ Supports broader use post-MI

Grateful to my co-authors &amp; mentors!🙌

[Pedro Gabriel Scardini @pedroscardini]

@h2h_research Amazing👏👏👏

[Heart2Heart Research Group @h2h_research]

Hello #MedTwitter!!

We are the Heart-2-Heart Research Group!🌟
We are made of ambitious med students and physicians from 🇧🇷
We aim to produce high-impact research in #Cardiology 🫀 with rigorous methodological standards.

Let’s connect #cardiotwitter!!🫀🫀

[Ana Carolina Covre Coan @AnaCCoan]

Very grateful for having found this dedicated group that is always teaching me! (Missing a few participants in the photo) 🤝🏼💕

[Pedro Gabriel Scardini @pedroscardini]

@christiankfuku @RCardoso_MD @metaacademy_ofc @Alonzo_Prata @marques_julia_ @AnaCCoan congrats on the hard work!! It is just the beginning

[Pedro Gabriel Scardini @pedroscardini]

Congrats on this solid work! More to come for sure.

[Alonzo Armani Prata @Alonzo_Prata]

Leaving Chicago with amazing news: just found out another paper has been accepted for publication! Grateful for this trip, and it couldn’t have ended on a better note. I’ll share more about the paper soon! #MedX #MedTwitter

[Pedro Gabriel Scardini @pedroscardini]

@Mahmoud_Ismayl @MayoProceedings @JAHA_AHA @DrAbdilahi_M @PanithayaC @claireraph @AGoldsweig @MayoClinic @MayoClinicCV @MayoCVFellows Congratulations on your research!! Best of luck.

[Pedro Gabriel Scardini @pedroscardini]

@IvoQueiroz2000 Nice meeting you, Ivo. Best of luck in the near future.

[Pedro Gabriel Scardini @pedroscardini]

@christiankfuku @AHAScience @erickatsuyama97 👏👏👏👏👏